Acute Labetalol Use in Preeclampsia

Acute Labetalol Use in Preeclampsia Randomized Trial

NCT03872336•Albany Medical College

Summary

The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.

Detailed Description

The investigators seek to asses the effect of obesity (BMI\>30) on severe hypertension control in patients with preeclampsia with severe features. The investigators hypothesize that successive administration of 40-60-80 mg of labetolol will reduce time to blood pressure control versus the standard dosing, 20-40-80 mg labetolol, recommended by the American College of Obstetricians and Gynecologists in 2015.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•BMI ≥ 30
•Age ≥ 18 years
•Gestational age ≥ 24 weeks
•Singleton gestation
•One sustained severe range blood pressure at Albany Medical Center

Exclusion Criteria

•Known allergic reaction to labetlol
•Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)
•Obstructive airway disease
•Bradycardia \< 70 beats/min
•Heart block \> 1st degree or history of heart failure

Locations (1)

Albany Medical Center Obstetrics and Gynecology

Albany, New York, United States

Key Dates

Start Date

February 18, 2019

Primary Completion Date

July 20, 2020

Completion Date

July 20, 2020

Last Updated

July 22, 2020

Enrollment

ACTUAL participants

Conditions

Preeclampsia With Severe Features

Interventions

Experimental labetalol dose

DRUG

Current standard of care

OTHER

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

NCT05096728

Preeclampsia With Severe Features

View study

TERMINATEDPHASE4

Acute Control of Chronic Hypertension

NCT03877692

Preeclampsia With Severe FeaturesChronic Hypertension in Obstetric Context

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 22, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions